Article Text

Download PDFPDF

Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis
  1. Shih-Wei Lai1,2,
  2. Yu-Hung Kuo3,
  3. Kuan-Fu Liao4,5
  1. 1College of Medicine, China Medical University, Taichung, Taiwan
  2. 2Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan
  4. 4College of Medicine, Tzu Chi University, Hualien, Taiwan
  5. 5Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao; kuanfuliaog{at}gmail.com

Statistics from Altmetric.com

Proton pump inhibitors are commonly prescribed for the treatment of acid-related gastrointestinal diseases. The association between proton pump inhibitors therapy and other subsequent comorbidities has been extensively explored.1 Recently, a cohort study in USA conducted by Ozen et al published in the Annals of the Rheumatic Diseases reported that proton pump inhibitors therapy was not associated with increased fracture risk in patients with rheumatoid arthritis (HR=0.92; 95% CI 0.80 to 1.06).2 Ozen et al’s study is an important one and deserves a practical value. Some points not shown in the original article are shared with the readers. First, in order to test …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles